Comparative Pharmacology
Head-to-head clinical analysis: QUALAQUIN versus QUINIDINE GLUCONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUALAQUIN versus QUINIDINE GLUCONATE.
QUALAQUIN vs QUINIDINE GLUCONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Class Ia antiarrhythmic agent; blocks sodium channels (Nav1.5) and potassium channels (IKr, IKs), prolongs action potential duration and effective refractory period; also has anticholinergic and alpha-adrenergic blocking effects.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
324-648 mg orally every 8-12 hours; maximum 3.24 g/day. Also administered IV as quinidine gluconate 200-400 mg (diluted) at a rate ≤1 mL/min.
None Documented
None Documented
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Terminal elimination half-life: 6-8 hours (range 4-12 hours) in healthy adults; prolonged in HF, renal impairment, or elderly.
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Renal: 50-70% unchanged; Biliary/fecal: 20-30%; Hepatic metabolism accounts for 10-30%.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)